PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models
Open Access
- 19 March 2019
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (23) , 2252-2269
Abstract
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor modelsKeywords
This publication has 52 references indexed in Scilit:
- Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FCNeuro-Oncology, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Toxicity profiles of immunotherapyPharmacology & Therapeutics, 2018
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscapeEuropean Journal of Cancer, 2017
- Immune System, Friend or Foe of Oncolytic Virotherapy?Frontiers in Oncology, 2017
- Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma modelNeuro-Oncology, 2017
- Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of CancerArthritis & Rheumatology, 2017
- Blockade of Type I Interferon (IFN) Production by Retroviral Replicating Vectors and Reduced Tumor Cell Responses to IFN Likely Contribute To Tumor SelectivityJournal of Virology, 2014
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vectorNeuro-Oncology, 2011